<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2023-22-4-95-105</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1857</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАКТИЧЕСКИЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ И ВАКЦИНОПРОФИЛАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRACTICAL ASPECTS OF EPIDEMIOLOGY AND VACCINE PREVENTION</subject></subj-group></article-categories><title-group><article-title>Организация массовой вакцинопрофилактики в условиях современного мегаполиса</article-title><trans-title-group xml:lang="en"><trans-title>Organization of Mass Vaccine Prevention in the Conditions of a Modern Megapolis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3565-2124</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Старшинин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Starshinin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Викторович Старшинин – кандидат медицинских наук, заместитель руководителя</p><p>Москва</p></bio><bio xml:lang="en"><p>Andrey V. Starshinin – Cand. Sci. (Med.), Deputy Head </p><p>Moscow</p></bio><email xlink:type="simple">StarshininAV@mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8987-4772</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елагина</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Elagina</surname><given-names>T. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Николаевна Елагина – главный врач</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatyana N. Elagina – head physician </p><p>Moscow</p></bio><email xlink:type="simple">ElaginaTN@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7660-3495</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Ю. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>Yu. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлия Борисовна Новикова – кандидат медицинских наук, заведующая отделом</p><p>Москва</p></bio><bio xml:lang="en"><p>Yulia B. Novikova – Cand. Sci. (Med.), department head </p><p>Moscow</p></bio><email xlink:type="simple">NovikovaYB@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грибановская</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gribanovskaya</surname><given-names>G. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Анатольевна Грибановская – заведующая отделом</p><p>Москва</p></bio><bio xml:lang="en"><p>Galina N. Gribanovskaya – department head </p><p>Moscow</p></bio><email xlink:type="simple">GribanovskayaGA@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0925-5822</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Камынина</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamynina</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Николаевна Камынина – доктор медицинских наук, заместитель директора по научной работе</p><p>115088, Москва, ул. Шарикоподшипниковская, д. 9</p></bio><bio xml:lang="en"><p>Natalya N. Kamynina – Dr. Sci. (Med.), Deputy Director for Research</p><p>9, Sharikopodshipnikovskaya street, Moscow, 115088</p></bio><email xlink:type="simple">niiozmm@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нечаев</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Nechaev</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Игоревич Нечаев – кандидат медицинских наук, научный сотрудник</p><p>Москва</p></bio><bio xml:lang="en"><p>Oleg I. Nechaev – Cand. Sci. (Med.), Researcher </p><p>Moscow</p></bio><email xlink:type="simple">NechaevOI@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Департамент здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ города Москвы «Центр медицинской профилактики Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budgetary Healthcare Institution «Сentre of Medical prevention Department of Healthcarew of Moscow»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУ города Москвы «НИИ организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budgetary Institution «Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>21</day><month>09</month><year>2023</year></pub-date><volume>22</volume><issue>4</issue><fpage>95</fpage><lpage>105</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Старшинин А.В., Елагина Т.Н., Новикова Ю.Б., Грибановская Г.А., Камынина Н.Н., Нечаев О.И., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Старшинин А.В., Елагина Т.Н., Новикова Ю.Б., Грибановская Г.А., Камынина Н.Н., Нечаев О.И.</copyright-holder><copyright-holder xml:lang="en">Starshinin A.V., Elagina T.N., Novikova Y.B., Gribanovskaya G.N., Kamynina N.N., Nechaev O.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1857">https://www.epidemvac.ru/jour/article/view/1857</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Во многих странах благодаря принимаемым на государственном уровне решениям удалось значительно повысить охват населения профилактическими прививками, снизить смертность от болезней, предупреждаемых с помощью вакцин. Однако пандемия COVID-19 вновь сделала актуальными вопросы организации массовой вакцинопрофилактики. Исходя из текущей эпидемиологической ситуации, характеристик населения, особенностей инфраструктуры, объема имеющихся ресурсов в каждой стране, отдельном городе разрабатывались и внедрялись различные организационные решения, направленные на вакцинацию населения. Московский опыт вакцинации населения против гриппа в мобильных прививочных пунктах у станций Московского метрополитена в 2016 г. стал отправной точкой в создании новых организационных форм и технологий массовой вакцинации жителей мегаполиса, которые в период пандемии COVID-19 были успешно адаптированы под новые условия.</p></sec><sec><title>Цель</title><p>Цель. Обобщение опыта проведения массовой вакцинации в сжатые сроки в условиях крупного мегаполиса (на примере Москвы).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование проведено по результатам поиска данных в базах цифровой платформы Google и PubMed. Отбирали материалы, публиковавшиеся в 2017–2023 гг. Анализ многолетней динамики заболеваемости гриппом в Российской Федерации, Центральном федеральном округе (ЦФО) и Москве был проведен по данным формы № 2 Федерального статистического наблюдения «Сведения об инфекционных и паразитарных заболеваниях» за 2013–2019 гг.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Анализ опыта разных стран показал, что разработка и внедрение новых форм организации массовой иммунизации не может быть «типовым проектом». В каждом регионе мира организация вакцинации проходит с учетом экономических, юридических, социальных, медицинских, организационных и даже культурологических условий. Так, например, в Москве организация вакцинации населения против гриппа в мобильных прививочных пунктах у станций Московского метрополитена способствовала снижению заболеваемости гриппом на 42,3% (с 24,6 в 2016 г. до 14,2 на 100 тыс. населения в 2017г.). В 2019 г. заболеваемость гриппом в Москве была на 28,8% ниже, чем в ЦФО, и на 62,2% ниже, чем в целом по России. Признанный удачным опыт размещения мобильных пунктов вакцинации около станций метро был значительно расширен для борьбы с пандемией COVID-19, когда были созданы выездные бригады, пункты в торговых центрах и др.</p></sec><sec><title>Заключение</title><p>Заключение. Проведенное исследование и данные литературы свидетельствуют о целесообразности создания дополнительных мест вакцинации для обеспечения необходимого охвата населения прививками за короткий период времени.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Thanks to decisions taken at the national level, many countries have managed to significantly increase coverage with preventive vaccination and reduce mortality from vaccine-preventable diseases. However, the COVID-19 pandemic has recaptured the relevance of organizing mass vaccination. Based on the current epidemiological situation, characteristics of the population, peculiar features of infrastructure, available resources in individual country, and individual city, various organizational vaccination solutions have been developed and implemented. The Moscow-based experience of vaccinating against influenza at mobile vaccination sites near the Moscow metro stations in 2016 became the starting point in the development of new organizational forms and technologies for mass vaccination in a megapolis, that have been successfully adapted to the new conditions of the COVID19 pandemic.</p></sec><sec><title>Aims</title><p>Aims. is to summarize foreign and Russian (exemplified by Moscow) experience in organizing mass vaccination.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study is based on the publication search results in Google and PubMed. The authors selected materials published in 2017– 2023. The implemented analysis of the long-term dynamics in the influenza incidence in the Russian Federation, the Central Federal District (CFD) and Moscow was based on data of the Federal State Statistical Observation Form No. 2 «Information on infectious and parasitic diseases» for 2013–2019.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The analysis of foreign experience shows that the development and implementation of new forms of mass vaccination cannot become a "standard project". In each region of the world, it is organized with due regard to the local economic, legal, social, medical, organizational and even cultural conditions. Vaccination of the population against influenza at mobile vaccination sites near the Moscow metro stations contributed to a 42.3% decrease in the incidence of influenza (from 24.6 in 2016 to 14.2 per 100,000 population in 2017). In 2019, the incidence of influenza in Moscow was 28.8% lower than the CFD one and 62.2% lower than the Russian rate. The recognized successful experience of deploying mobile vaccination sites near the metro stations has been significantly expanded to control the COVID-19 pandemic with mobile teams, vaccination sites in shopping centers, etc.</p></sec><sec><title>Conclusion</title><p>Conclusion. The conducted research and literature data substantiate the deployment of additional vaccination sites to ensure the necessary coverage with vaccination within a short period of time.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>массовая вакцинация</kwd><kwd>центры массовой вакцинации</kwd><kwd>доступность</kwd><kwd>программы вакцинации</kwd><kwd>грипп</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mass vaccination</kwd><kwd>mass vaccination centers</kwd><kwd>accessibility</kwd><kwd>vaccination programs</kwd><kwd>influenza</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Facciolà A, Visalli G. Past and Future of Vaccinations: From Jenner to Nanovaccinology // Vaccines (Basel). 2023 Feb 7, № 11(2). P. 384. 2. Conis E. Measles and the Modern History of Vaccination. Public Health Rep. 2019 Mar/Apr, № 134(2). P. 118–125.</mixed-citation><mixed-citation xml:lang="en">Facciolà A, Visalli G. Past and Future of Vaccinations: From Jenner to Nanovaccinology. Vaccines (Basel). 2023 Feb 7; 11(2):384. doi: 10.3390/vaccines11020384.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hayman DTS. Measles vaccination in an increasingly immunized and developed world // Hum Vaccin Immunother. 2019; № 15(1). P. 28–33.</mixed-citation><mixed-citation xml:lang="en">Conis E. Measles and the Modern History of Vaccination. Public Health Rep. 2019 Mar/Apr;134(2):118–125. doi: 10.1177/0033354919826558.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues // Hum Vaccin Immunother. 2021 Dec 2; № 17(12). P. 5255–5268.</mixed-citation><mixed-citation xml:lang="en">Hayman DTS. Measles vaccination in an increasingly immunized and developed world. Hum Vaccin Immunother. 2019;15(1):28-33. doi: 10.1080/21645515.2018.1517074.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch S, Jasny E, Schmidt KE, Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018 Sep 19; № 9: Р.1963.</mixed-citation><mixed-citation xml:lang="en">Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother. 2021 Dec 2; 17(12): 5255–5268. doi: 10.1080/21645515.2021.1977057.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Qu M, Zhou X, Li H. BCG vaccination strategies against tuberculosis: updates and perspectives. Hum Vaccin Immunother. 2021 Dec 2; № 17(12). Р. 5284–5295.</mixed-citation><mixed-citation xml:lang="en">Rauch S, Jasny E, Schmidt KE, Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018 Sep 19;9:1963. doi: 10.3389/fimmu.2018.01963.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mohanty P, Jena P, Patnaik L. Vaccination against Hepatitis B: A Scoping Review. Asian Pac J Cancer Prev. 2020 Dec 1; № 21(12). Р. 3453–3459.</mixed-citation><mixed-citation xml:lang="en">Qu M, Zhou X, Li H. BCG vaccination strategies against tuberculosis: updates and perspectives. Hum Vaccin Immunother. 2021 Dec 2;17(12):5284–5295. doi: 10.1080/21645515.2021.2007711.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Magno H, Golomb B. Measuring the Benefits of Mass Vaccination Programs in the United States. Vaccines (Basel). 2020 Sep 29; № 8(4). Р. 561.</mixed-citation><mixed-citation xml:lang="en">Mohanty P, Jena P, Patnaik L. Vaccination against Hepatitis B: A Scoping Review. Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3453–3459. doi: 10.31557/APJCP.2020.21.12.3453.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer D, Shearer MP, Chih YC, et al. Taiwan’s Annual Seasonal Influenza Mass Vaccination Program-Lessons for Pandemic Planning.Am J Public Health. 2018 Sep; № 108(S3) Р. 188–193.</mixed-citation><mixed-citation xml:lang="en">Magno H, Golomb B. Measuring the Benefits of Mass Vaccination Programs in the United States. Vaccines (Basel). 2020 Sep 29;8(4):561. doi: 10.3390/vaccines8040561.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cuschieri S, Agius S, Souness J, et al. The fastest national COVID vaccination in Europe – Malta’s strategies.Health Sci Rev (Oxf). 2021; № 1: Р. 100001.</mixed-citation><mixed-citation xml:lang="en">Meyer D, Shearer MP, Chih YC, et al. Taiwan’s Annual Seasonal Influenza Mass Vaccination Program-Lessons for Pandemic Planning. Am J Public Health. 2018 Sep;108(S3):S188–S193. doi: 10.2105/AJPH.2018.304527.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee L, Peterson GM, Naunton M, Jackson S, Bushell M. Protecting the Herd: Why Pharmacists Matter in Mass Vaccination.Pharmacy (Basel). 2020 Oct 26; № 8(4). Р. 199.</mixed-citation><mixed-citation xml:lang="en">Cuschieri S, Agius S, Souness J, et al. The fastest national COVID vaccination in Europe Malta’s strategies. Health Sci Rev (Oxf). 2021;1:100001. doi: 10.1016/j.hsr.2021.100001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shakory S, Eissa A, Kiran T, Pinto AD. Best Practices for COVID-19 Mass Vaccination Clinics.Ann Fam Med. 2022 Mar-Apr; № 20(2) Р. 149–156.</mixed-citation><mixed-citation xml:lang="en">Lee L, Peterson GM, Naunton M, Jackson S, Bushell M. Protecting the Herd: Why Pharmacists Matter in Mass Vaccination. Pharmacy (Basel). 2020 Oct 26;8(4):199. doi: 10.3390/pharmacy8040199.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Филиппов О. В., Большакова Л. Н., Ермишина Ю. В. и др. Опыт организации в условиях мегаполиса мобильных прививочных пунктов для вакцинации взрослого населения против гриппа. Эпидемиология и Вакцинопрофилактика. 2017. № 16(4). С. 22–27.</mixed-citation><mixed-citation xml:lang="en">Shakory S, Eissa A, Kiran T, Pinto AD. Best Practices for COVID-19 Mass Vaccination Clinics. Ann Fam Med. 2022 Mar-Apr;20(2):149–156. doi: 10.1370/afm.2773.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Боровикова З. В. Оспа и вакцинация: исторический аспект.Вестник общественных и гуманитарных наук. 2021. Т. 2. No 4. С. 19–23.</mixed-citation><mixed-citation xml:lang="en">Filippov OV, Bolshakova LN, Ermishina YV, et al. Experience in Organizing in Metropolis Mobile Immunization to Vaccinate Adults against Flu. Epidemiology and Vaccinal Prevention. 2017;16(4):22–27. (In Russ.) doi.org/10.31631/2073-3046-2017-16-4-22-27.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Всемирная организация здравоохранения (2018). Отчет об оценке Глобального плана действий в отношении вакцин за 2018 г.: стратегическая консультативная группа экспертов по иммунизации. Доступно на: https://apps.who.int/iris/handle/10665/276967.</mixed-citation><mixed-citation xml:lang="en">Borovikova ZV. Smallpox and vaccination: a historical aspect.Vestnik obshchestvennyh i gumanitarnyh nauk. 2021;2(4):19–23. (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Европейская повестка дня в области иммунизации на период до 2030 г. Копенгаген: Европейское региональное бюро ВОЗ; 2022 г. .Доступно на: https://www.who.int/europe/ru/publications/i/item/9789289056052.</mixed-citation><mixed-citation xml:lang="en">World Health Organization (2018). 2018 assessment report of the Global Vaccine Action Plan: strategic advisory group of experts on immunization. Available at: https://apps.who.int/iris/handle/10665/276967.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gianfredi V., Pennisi F., Lume A., et al. Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature. Vaccines. 2021 Vol. 9 P. 574.</mixed-citation><mixed-citation xml:lang="en">European Immunization Agenda 2030. Copenhagen: WHO Regional Office for Europe; 2021. Available at: https://apps.who.int/iris/handle/10665/276967.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Barranco R., Rocca G., Molinelli A., et al. Controversies and Challenges of Mass Vaccination against SARS-CoV-2 in Italy: Medico-Legal Perspectives and Considerations.Healthcare (Basel). 2021 Vol. 9(9) P. 1163.</mixed-citation><mixed-citation xml:lang="en">Gianfredi V, Pennisi F, Lume A, et al. Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature. Vaccines 2021;9:574. doi:10.3390/vaccines9060574.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Aman Gupta, Gerald W. Evans, Sunderesh S. Heragu, Simulation and optimization modeling for drive-through mass vaccination – A generalized approach. Simulation Modelling Practice and Theory, V. 37, 2013, P. 99–106.</mixed-citation><mixed-citation xml:lang="en">Barranco R, Rocca G, Molinelli A, et al. Controversies and Challenges of Mass Vaccination against SARS-CoV-2 in Italy: Medico-Legal Perspectives and Considerations. Healthcare (Basel). 2021;9(9):1163. doi:10.3390/healthcare9091163.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss EA, Ngo J, Gilbert GH, Quinn JV. Drive-through medicine: a novel proposal for rapid evaluation of patients during an influenza pandemic. Ann Emerg Med. 2010 Mar; № 55(3). Р. 268–73.</mixed-citation><mixed-citation xml:lang="en">Aman Gupta, Gerald W. Evans, Sunderesh S. Heragu, Simulation and optimization modeling for drive-through mass vaccination – A generalized approach, Simulation Modelling Practice and Theory, 37, 2013: 99–106, https://doi.org/10.1016/j.simpat.2013.06.004.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Buck, B., Cowan, L., Smith, L., Duncan, E., Bazemore, J., &amp; Schwind, J. Effective Practices and Recommendations for Drive-Through Clinic Points of Dispensing: A Systematic Review. Disaster Medicine and Public Health Preparedness, 2021. № 15(3), Р. 374–388.</mixed-citation><mixed-citation xml:lang="en">Weiss EA, Ngo J, Gilbert GH, Quinn JV. Drive-through medicine: a novel proposal for rapid evaluation of patients during an influenza pandemic. Ann Emerg Med. 2010 Mar;55(3):268–73. doi: 10.1016/j.annemergmed.2009.11.025.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jiee SF, Bondi ME, Emiral ME, Jantim A. Polio Supplementary Immunization Activities During COVID-19 Pandemic: Experience from Penampang District, Sabah, Malaysia. Journal of Primary Care &amp; Community Health. 2021; № 12.</mixed-citation><mixed-citation xml:lang="en">Buck, B., Cowan, L., Smith, L., Duncan, E., Bazemore, J., &amp; Schwind, J. Effective Practices and Recommendations for Drive-Through Clinic Points of Dispensing: A Systematic Review. Disaster Medicine and Public Health Preparedness, 2021:15(3), 374–388. doi:10.1017/dmp.2020.15.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Goralnick E., Kaufmann C., Gawande A. Mass-Vaccination Sites – An Essential Innovation to Curb the Covid-19 Pandemic. New England Journal of Medicine. 2021 Vol. 384 P. 18.</mixed-citation><mixed-citation xml:lang="en">Jiee SF, Bondi ME, Emiral ME, Jantim A. Polio Supplementary Immunization Activities During COVID-19 Pandemic: Experience from Penampang District, Sabah, Malaysia. Journal of Primary Care &amp; Community Health. 2021;12. doi:10.1177/21501327211029800.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg S.A., Callaway D., Resnick-Ault D., et al. Critical Concepts for COVID-19 Mass Vaccination Site Operations. Disaster. Med Public Health Prep. 2021 Vol. 17 P. 60.</mixed-citation><mixed-citation xml:lang="en">Goralnick E, Kaufmann C, Gawande A. Mass-Vaccination Sites – An Essential Innovation to Curb the Covid-19 Pandemic. New England Journal of Medicine 2021;384:18 doi:10.1056/NEJMp2102535.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Smith D., Vanchiere J., Raley M., et al. COVID-19 drive-through mass vaccination in Northwest Louisiana.Journal La Public Health Assoc. 2022 Vol. 2(2) P. 30–41.</mixed-citation><mixed-citation xml:lang="en">Goldberg S, Callaway D, Resnick-Ault D, et al. Critical Concepts for COVID-19 Mass Vaccination Site Operations. Disaster Med Public Health Prep. 2021;17:e60. doi: 10.1017/dmp.2021.319.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">de Almeida L., Domingues J., Rewa T., et al. Implementation of the drive-through strategy for COVID-19 vaccination: an experience report. Rev Esc Enferm USP. 2022 Vol. 56 P. e20210397.</mixed-citation><mixed-citation xml:lang="en">Smith D, Vanchiere J, Raley M, et al. COVID-19 drive-through mass vaccination in Northwest Louisiana. Journal La Public Health Assoc. 2022;2(2):30–41.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sala F., D’Urso G., Giardini C. Discrete-event simulation study of a COVID-19 mass vaccination centre. Int J Med Inform. 2023. Vol. 170 P. 104940.</mixed-citation><mixed-citation xml:lang="en">de Almeida L, Domingues J, Rewa T, et al. Implementation of the drive-through strategy for COVID-19 vaccination: an experience report. Rev Esc Enferm USP. 2022;56:20210397. doi: 10.1590/1980-220XREEUSP-2021-0397en.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Signorelli C., Odone A., Gianfredi V., et al. Application of the «immunization islands» model to improve quality, efficiency and safety of a COVID-19 mass vaccination site. AnnIg. 2021 Vol. 33(5) P. 499–512.</mixed-citation><mixed-citation xml:lang="en">Sala F, D’Urso G, Giardini C. Discrete-event simulation study of a COVID-19 mass vaccination centre. Int J Med Inform. 2023;170:104940. doi: 10.1016/j.ijmedinf.2022.104940.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kotani H., Okai H., Tamura M. Mosque as a vaccination site for ethnic minority in Kanagawa, Japan: leaving no one behind amid the COVID-19 pandemic. disaster. Med Public Health Prep. 2022 Vol. 23. P. 1–9.</mixed-citation><mixed-citation xml:lang="en">Signorelli C, Odone A, Gianfredi V, et al. Application of the «immunization islands» model to improve quality, efficiency and safety of a COVID-19 mass vaccination site. AnnIg. 2021;33(5):499–512. doi:10.7416/ai.2021.2456.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura M., Kotani H., Katsura Y., et al. Mosque as a COVID-19 vaccination site in collaboration with a private clinic: A short report from Osaka, Japan. Prog Disaster Sci. 2022 Vol. 16. P. 100263.</mixed-citation><mixed-citation xml:lang="en">Kotani H, Okai H, Tamura M. Mosque as a vaccination site for ethnic minority in Kanagawa, Japan: leaving no one behind amid the COVID-19 pandemic. Disaster Med Public Health Prep. 2022;23:1–9. doi: 10.1017/dmp.2022.78.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Çetinkaya C., Erbaş M., Kabak M., et al. A mass vaccination site selection problem: An application of GIS and entropy-based MAUT approach. Socioecon Plann Sci. 2023. Vol. 85. P. 101376.</mixed-citation><mixed-citation xml:lang="en">Tamura M, Kotani H, Katsura Y, et al. Mosque as a COVID-19 vaccination site in collaboration with a private clinic: A short report from Osaka, Japan. Prog Disaster Sci. 2022;16:100263. doi: 10.1016/j.pdisas.2022.100263.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo, F. and H., Jingyuan and Long, Elisa, Closer to Home: Partnering to Distribute Vaccinations under Spatially Heterogeneous Demand. .Доступно на: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4008669.</mixed-citation><mixed-citation xml:lang="en">Çetinkaya C, Erbaş M, Kabak M, et al. A mass vaccination site selection problem: An application of GIS and entropy-based MAUT approach. Socio-Economic Planning Sciences | Journal. 2023;85:101376. doi: 10.1016/j.seps.2022.101376.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hanly M, Churches T., Fitzgerald O., et al. Modelling vaccination capacity at mass vaccination hubs and general practice clinics: a simulation study. BMC Health Serv Res. 2022. Vol. 22(1). P. 1059.</mixed-citation><mixed-citation xml:lang="en">Bravo, F. and H., Jingyuan and Long, Elisa, Closer to Home: Partnering to Distribute Vaccinations under Spatially Heterogeneous Demand. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4008669.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Qi F., Barragan D., Rodriguez M.G., et al. Evaluating spatial accessibility to COVID-19 vaccine resources in diversely populated counties in the United States. Front Public Health. 2022. Vol. 10. P. 89553–8.</mixed-citation><mixed-citation xml:lang="en">Hanly M, Churches T, Fitzgerald O, et al. Modelling vaccination capacity at mass vaccination hubs and general practice clinics: a simulation study. BMC Health Serv Res. 2022;22(1):1059. doi: 10.1186/s12913-022-08447-8.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mohamed Suliman D., Nawaz F.A., Mohanan P., et al. UAE efforts in promoting COVID-19 vaccination and building vaccine confidence. Vaccine. 2021. Vol. 5. P. 6341–6345.</mixed-citation><mixed-citation xml:lang="en">Qi F, Barragan D, Rodriguez M, et al. Evaluating spatial accessibility to COVID-19 vaccine resources in diversely populated counties in the United States. Front Public Health. 2022;10:895538. doi: 10.3389/fpubh.2022.895538.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tennant R., Tetui M., Grindrod K., et al. Multi-Disciplinary Design and Implementation of a Mass Vaccination Clinic Mobile Application to Support Decision-Making. Journal Transl Eng Health Med. 2022. Vol. 11. P. 60–69.</mixed-citation><mixed-citation xml:lang="en">Mohamed SD, Nawaz FA, Mohanan P, et al. UAE efforts in promoting COVID-19 vaccination and building vaccine confidence. Vaccine. 2021;5:6341–6345. doi: 10.1016/j.vaccine.2021.09.015.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Diegel-Vacek L., Reising V., Bertini K., et al. Leveraging an Academic Practice Partnership to Support a COVID-19 Mass Vaccination Clinic. Journal Nurs Educ. 2022 Vol. 61(6). P. 308–313.</mixed-citation><mixed-citation xml:lang="en">Tennant R, Tetui M, Grindrod K, et al. Multi-Disciplinary Design and Implementation of a Mass Vaccination Clinic Mobile Application to Support Decision-Making. Journal Transl Eng Health Med. 2022;11:60–69. doi: 10.1109/JTEHM.2022.3224740.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Rowh M., Rowh A., Lambert S., et al. Drive-Through Mass Vaccination Center Operations in a Rural, Medically Underserved Area Using Military Civilian Partnership During the COVID-19 Pandemic. Disaster Medicine and Public Health Preparedness, 2023. Vol. 17. P. 354.</mixed-citation><mixed-citation xml:lang="en">Diegel-Vacek L, Reising V, Bertini K, et al. Leveraging an Academic Practice Partnership to Support a COVID-19 Mass Vaccination Clinic. Journal Nurs Educ. 2022;61(6):308–313. doi: 10.3928/0148483420220404-17.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hess K., Bach A., Won K., et al. Community Pharmacists Roles During the COVID-19 Pandemic.Journal of Pharmacy Practice. 2022. Vol. 35(3). P. 469–476.</mixed-citation><mixed-citation xml:lang="en">Rowh M, Rowh A, Lambert S, et al. Drive-Through Mass Vaccination Center Operations in a Rural, Medically Underserved Area Using Military Civilian Partnership During the COVID-19 Pandemic. Disaster Medicine and Public Health Preparedness, 2023;17:e354. doi:10.1017/dmp.2023.25.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">McConeghy KW, Wing C. A national examination of pharmacy-based immunization statutes and their association with influenza vaccinations and preventive health. Vaccine, 2016. Vol. 34(30). P. 3463–3468.</mixed-citation><mixed-citation xml:lang="en">Hess K, Bach A, Won K, et al. Community Pharmacists Roles During the COVID-19 Pandemic. Journal of Pharmacy Practice. 2022;35(3):469–476. doi:10.1177/0897190020980626.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Patel AR, Breck AB, Law MR. The impact of pharmacy-based immunization services on the likelihood of immunization in the United States. Journal of the American Pharmacists Association, 2018. Vol. 58(5). P. 505–514.</mixed-citation><mixed-citation xml:lang="en">McConeghy KW, Wing C. A national examination of pharmacy-based immunization statutes and their association with influenza vaccinations and preventive health. Vaccine. 2016 Jun 24;34(30):3463– 8. doi: 10.1016/j.vaccine.2016.04.076.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Angela K. Peterson Sh. and A. The pharmacist and pharmacy have evolved to become more than the corner drugstore: a win for vaccinations and public health. Human Vaccines &amp; Immunotherapeutics, 2016. Vol. 5. P. 1178–1180.</mixed-citation><mixed-citation xml:lang="en">Patel AR, Breck AB, Law MR. The impact of pharmacy-based immunization services on the likelihood of immunization in the United States. J Am Pharm Assoc (2003). 2018. Sep-Oct;58(5):505–514.e2. doi: 10.1016/j.japh.2018.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Melissa L. Martinez, Sarah Coles, Addressing Immunization Health Disparities. Primary Care: Clinics in Office Practice, V. 47, I. 3, 2020, P. 483–495.</mixed-citation><mixed-citation xml:lang="en">Angela KS, Peterson A. The pharmacist and pharmacy have evolved to become more than the corner drugstore: a win for vaccinations and public health. Human Vaccines &amp; Immunotherapeutics, 2016;5:1178-1180. doi: 10.1080/21645515.2019.1660119.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">AlMahasis S., Fox B., Ha D., et al. Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states. Vaccine. 2023 Vol. 41(15). P. 2503–2513.</mixed-citation><mixed-citation xml:lang="en">Melissa L. Martinez, Sarah Coles, Addressing Immunization Health Disparities. Primary Care: Clinics in Office Practice, 2020;47(3):483–495. doi.org/10.1016/j.pop.2020.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Rose O., Erzkamp S., Schöbel W., et al. COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction. Vaccine. 2022. Vol. 40(35). P. 5207–5212.</mixed-citation><mixed-citation xml:lang="en">AlMahasis SO, Fox B, Ha D, et al. Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states. Vaccine. 2023;41(15):2503– 2513. doi: 10.1016/j.vaccine.2023.03.002.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Boulliat C., Malachane A.S., Massoubre B. Vaccination contre la COVID-19 dans les officines en région Auvergne-Rhône-Alpes. Étude menée trois mois après le début de la vaccination [Vaccination against COVID-19 in pharmacies in the Auvergne-Rhône-Alpes region. Study conducted three months after the start of vaccination]. Ann Pharm Fr. 2022. Vol. 80(4). P. 486–493.</mixed-citation><mixed-citation xml:lang="en">Rose O, Erzkamp S, Schöbel W, et al. COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction. Vaccine. 2022;40(35):5207–5212. doi: 10.1016/j.vaccine.2022.07.034.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Merks P., Kowalczuk A., Wong A., et al. Patient satisfaction with pharmacist-administered COVID-19 vaccines in Poland: a survey study in the vaccination centres context.BMC Health Serv Res. 2022. Vol. 22(1). P. 1339.</mixed-citation><mixed-citation xml:lang="en">Boulliat C, Malachane AS, Massoubre B. Vaccination contre la COVID-19 dans les officines en région Auvergne-Rhône-Alpes. Étude menée trois mois après le début de la vaccination [Vaccination against COVID-19 in pharmacies in the Auvergne-Rhône-Alpes region. Study conducted three months after the start of vaccination]. Ann Pharm Fr. 2022;80(4):486–493. doi: 10.1016/j.pharma.2021.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Merks P, Kowalczuk A, Wong A, et al. Patient satisfaction with pharmacist-administered COVID-19  vaccines in Poland: a survey study in the vaccination centres context. BMC Health Serv Res. 2022;22(1):1339. doi: 10.1186/s12913-022-08720-w.</mixed-citation><mixed-citation xml:lang="en">Merks P, Kowalczuk A, Wong A, et al. Patient satisfaction with pharmacist-administered COVID-19  vaccines in Poland: a survey study in the vaccination centres context. BMC Health Serv Res. 2022;22(1):1339. doi: 10.1186/s12913-022-08720-w.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
